Citations

Showing 10 of 108094 citations.

Weight suppression as a predictor variable in the treatment of eating disorders: A systematic review
Jenkins, Paul E. , Lebow, Jocelyn , Rienecke, Renee D. , Jenkins, P E , Lebow, Jocelyn

Mayo Clinic

Journal of Psychiatric and Mental Health Nursing | April 21, 2018 | Volume: 25 | Issue: 5-6 | Pages: 297-306

10.1111/jpm.12462 | PMID 29679513 Get It

Accessible summaryWhat is known on the subject? Weight suppression (WS) has been suggested to predict outcome following psychological treatment for an eating disorder (ED). Some findings are contradictory and have not been considered systematically. What the paper adds to existing knowledge? The review suggests that weight gain at post‐treatment is reliably predicted by pretreatment WS, but findings regarding other outcomes (e.g., treatment dropout) are less consistent. Approximate effect sizes for observed relationships are identified, alongside support for biobehavioural theories of metabolic adaptation to weight loss. What are the implications for practice? Degree of WS at pretreatment is associated with weight gain and is important for clinicians to consider before offering treatment to patients with EDs. Patients high in WS might benefit from further support (e.g., psychoeducation) prior to beginning treatment. AbstractIntroductionWeight suppression (WS—the difference between highest body weight and current body weight) has been proposed as a predictor of treatment outcome within eating disorders (EDs), although this hypothesis has not been consistently supported.Aim/QuestionReview the association between pretreatment WS and outcome following psychological treatment for EDs.MethodA comprehensive electronic database search for published and unpublished literature from 1979 to 2017. Reference lists were also inspected. Eligibility criteria were determined according to relevant guidelines and a quality appraisal was conducted.ResultsTwelve studies met inclusion criteria (one was subsequently excluded based on insufficient data). Greater WS was generally associated with weight gain at post‐treatment although not with other treatment outcomes.DiscussionThe existing evidence, with data from 1,566 participants, is summarized according to three main post‐treatment outcomes: weight change; treatment completion; and symptom abstinence. Patients with disordered eating and greater WS may need to gain more weight than others during treatment to achieve good outcomes. Recommendations for future studies are provided.Implications for practiceEvidence‐based treatments for EDs may benefit from considering WS when planning treatment, such as further psychoeducation on weight changes. Societal interventions regarding promotion of healthy eating may also draw on these findings.
Consensus Statement on Use of Continuous Subcutaneous Insulin Infusion Therapy in the Hospital
Thompson, Bithika , Klonoff, David C. , Cook, Curtiss B. , Korytkowski, Mary T. , Klonoff, David C.

Mayo Clinic

Journal of Diabetes Science and Technology | April 21, 2018 | Volume: 12 | Issue: 4 | Pages: 880-889

10.1177/1932296818769933 | PMID 29681173 Get It

In May 2017, the Diabetes Technology Society convened a panel of US experts on inpatient diabetes management to discuss the current and potential role of continuous subcutaneous insulin infusion (CSII) therapy in the hospital. The panel (1) discussed evidence for current use of CSII in the hospital, (2) recommended contraindications for use in the hospital, and (3) recommended guidelines to maximize chances for safe use of CSII in the hospital. Panel members agreed that larger, prospective, randomized studies are needed to evaluate safety and efficacy of CSII use in the hospital. As CSII technology becomes more complex and its use increases, it is imperative that institutional protocols be in place to ensure safe use of this technology and safe transitions across care areas. Providers need to be cognizant that not all patients currently using CSII as an outpatient are appropriate candidates for continued use in the hospital. This consensus statement provides guidelines for practitioners who may encounter patients using this technology in the inpatient setting.
Outcomes After Cardiac Transplant for Wild Type Transthyretin Amyloidosis
Rosenbaum, Andrew , AbouEzzeddine, Omar F. , Grogan, Martha , Kushwaha, Sudhir S. , Clavell, Alfredo L. , Daly, Richard C. , Edwards, Brooks S., Rosenbaum, Andrew N , Kushwaha, Sudhir, Clavell, Alfredo, Dispenzieri, Angela , AbouEzzeddine, Omar F

Mayo Clinic

Transplantation | April 20, 2018 | Volume: 102 | Issue: 11 | Pages: 1909-1913

10.1097/tp.0000000000002240 | PMID 29677073 Get It

Background The true prevalence of heart failure due to wild type transthyretin amyloidosis (ATTRwt) is likely underestimated. There is a paucity of data with regard to the management of ATTRwt-related advanced heart failure and the natural history of extracardiac ATTRwt. Methods We conducted a retrospective cohort study of patients undergoing cardiac transplant (HTx) for ATTRwt at a single institution. Comprehensive clinical data, including baseline hemodynamic and echocardiographic characteristics, and posttransplant outcomes, were obtained. Results Seven patients with ATTRwt underwent HTx between 2007 and 2015. All patients were male with a mean age of 66 ± 9. Patients had a reduced ejection fraction (mean, 37 ± 14%) and elevated filling pressures pre-HTx (mean pulmonary capillary wedge pressure 22 ± 7 mm Hg) before HTx. Three-year survival was 100%; 1 patient died of pancreatic cancer 45 months post-HTx (1 death per 30.8 patient-years). Oxygen consumption (Δ +6.8 ± 4.9 mL·kg−1·min−1) and 6-minute walk distances (Δ +189 ± 60 m) improved. Symptomatic gastrointestinal involvement (n = 2) and peripheral nerve involvement (n = 4) by ATTRwt developed late. Conclusions This is the first report of a series of ATTRwt patients receiving HTx in which excellent outcomes are demonstrated. Although cardiac death is averted, systemic manifestations of ATTRwt may develop posttransplantation.
Heavy Alcohol Use Among Deceased Donors Does Not Impact Recipient Outcomes After Liver Transplantation
Arora, Sumant, Chahal, Khushdeep, Axley, Page , Kuo, Yong‐Fang , Satapathy, Sanjaya K. , Wiesner, Russell H., Wiesner, Russell, Sathapathy, Sanjaya , Eckhoff, Devin E. , Singal, Ashwani K.

Mayo Clinic

Transplantation | April 20, 2018 | Volume: 102 | Issue: 11 | Pages: 1864-1869

10.1097/tp.0000000000002230 | PMID 29677070 Get It

BackgroundData on liver transplant (LT) outcomes using deceased donors with heavy drinking (HD) (>2 drinks per day) are scanty.MethodsUsing the United Network for Organ Sharing database (2002-2014), we examined outcomes after LT in adults comparing deceased HD donors with non-HD (ND) donors.ResultsOf 56 182 first LTs performed in the United States for 10 common indications using deceased donors, 47 882 with available information on alcohol use were analyzed. Of these 47 882 LT recipients, 7298 (15%) were from HD donors, with similar proportion over time (2002-2014, Armitage trend testP= 0.75) and for recipient liver disease etiology (χ2P= 0.42). Proportion of liver organ used for LT was lower for HD donors compared with ND donors (63% vs 78%;P< 0.001). Five-year outcomes on first LT comparing 7166 HD donors and 21 498 ND donors matched based on propensity score were similar for liver graft (73.7% vs 73.7%, log rankP= 0.98) and patient survival (77.6% vs 77.0%,P= 0.36). On Cox regression analysis, history of HD in deceased donors did not affect liver graft 1.02 (0.97-1.08) or patient survival 1.03 (0.97-1.09).ConclusionsAmong LT recipients using select liver grafts, history of HD in deceased donors does not impact outcomes after LT.
Phenotypic Antimicrobial Susceptibility Testing with Deep Learning Video Microscopy
Yu, Hui , Jing, Wenwen , Iriya, Rafael , Yang, Yunze , Syal, Karan , Mo, Manni , Grys, Thomas E. , Tao, Nongjian , Wang, Shaopeng , Yu, Hui , Haydel, Shelley E. , Wang, Shaopeng , Grys, Thomas E , Jing, Wenwen

Mayo Clinic

Analytical Chemistry | April 20, 2018 | Volume: 90 | Issue: 10 | Pages: 6314-6322

10.1021/acs.analchem.8b01128 | PMID 29677440 Get It

Supporting the Future of the Oncology Workforce: ASCO Medical Student and Trainee Initiatives
Leon‐Ferre, Roberto A. , Stover, Daniel G. , Stover, Daniel G

Mayo Clinic

Journal of Oncology Practice | April 20, 2018 | Volume: 14 | Issue: 5 | Pages: 277-280

10.1200/jop.17.00088 | PMID 29676949 Get It

Pictorial Review of Digital Radiography Artifacts
Walz‐Flannigan, Alisa , Brossoit, Kimberly J., Magnuson, Dayne, Schueler, Beth A. , Walz-Flannigan, Alisa I, Magnuson, Dayne J

Mayo Clinic

RadioGraphics | April 20, 2018 | Volume: 38 | Issue: 3 | Pages: 833-846

10.1148/rg.2018170038 | PMID 29676963 Get It

Can Lung Ultrasound Be the First-Line Tool for Evaluation of Intraoperative Hypoxemia?
Díaz‐Gómez, José L. , Ratzlaff, Robert A. , Torp, Klaus D. , Via, Gabriele , Díaz-Gómez, José L , Renew, J. Ross , Ramakrishna, Harish

Mayo Clinic

Anesthesia & Analgesia | April 20, 2018 | Volume: 126 | Issue: 6 | Pages: 2146-2147

10.1213/ane.0000000000002849 | PMID 29683826 Get It

Neuroembryology of the Acupuncture Principal Meridians: Part 3. The Head and Neck
Dorsher, Peter T. , Chiang, Poney

Mayo Clinic

Medical Acupuncture | April 20, 2018 | Volume: 30 | Issue: 2 | Pages: 80-88

10.1089/acu.2018.1271 | PMID 29682148 Get It

Essential Infantile Esotropia: Potential Pathogenetic Role of Extended Subcortical Neuroplasticity
Brodsky, Michael C.

Mayo Clinic

Investigative Opthalmology & Visual Science | April 20, 2018 | Volume: 59 | Issue: 5 | Pages: 1964

10.1167/iovs.18-23780 | PMID 29677359 Get It